Know Cancer

forgot password

Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis

18 Years
Open (Enrolling)
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma

Thank you

Trial Information

Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis

The investigators propose to contact and interact with all patients with plasma cell
dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical
Center) for both surveillance and research purposes in order to develop interventions
targeted to decrease their morbidity and mortality.

Inclusion Criteria


Diagnosis of a plasma cell dyscrasia


Prisoners are excluded from participation as they have no standard access to the Ohio
State myeloma clinic and would impede the research objective of this protocol.

Type of Study:

Observational [Patient Registry]

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio

Outcome Time Frame:

up to 3 years

Safety Issue:


Principal Investigator

Craig C Hofmeister, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University


United States: Institutional Review Board

Study ID:

OSU - 10115



Start Date:

March 2011

Completion Date:

Related Keywords:

  • Plasma Cell Dyscrasias
  • Monoclonal Gammopathy of Undetermined Significance
  • AL Amyloidosis
  • Multiple Myeloma
  • MGUS
  • Multiple Myeloma
  • Tissue Bank
  • Amyloidosis
  • Monoclonal Gammopathy of Undetermined Significance
  • Paraproteinemias
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Ohio State University Medical CenterColumbus, Ohio  43210